Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Boehringer Ingelheim
McKesson
Medtronic
AstraZeneca

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

NEULASTA Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for NEULASTA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Icahn School of Medicine at Mount SinaiPhase 1/Phase 2
University of Texas Southwestern Medical CenterEarly Phase 1
Centre Leon BerardPhase 2

See all NEULASTA clinical trials

Recent Litigation for NEULASTA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Amgen Inc. v. Apotex Inc2018-08-07
AMGEN INC v. MYLAN INC.2017-09-22
Amgen Inc. v. Apotex Inc.2016-10-04

See all NEULASTA litigation

Company Disclosures: US Patents for NEULASTA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-03 RX Orphan company
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-10 RX Orphan company
Amgen NEULASTA pegfilgrastim SYRINGE 125031 001 2002-01-31   Start Trial Amgen Inc. (Thousand Oaks, CA) 2039-02-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for NEULASTA

These patents were identified by searching patent claims

Supplementary Protection Certificates for NEULASTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
6/2003 Austria   Start Trial PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/227/001 20020822
2002C/040 Belgium   Start Trial PRODUCT NAME: PEGFILGRASTIM; AUTHORISATION NUMBER AND DATE: EU/1/02/227/001 20020823
5/2003 Austria   Start Trial PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822
300106 Netherlands   Start Trial PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822
02C0048 France   Start Trial PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/228/001 20020822
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Baxter
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.